Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity.
D000328:Adult; D001067:Appetite Depressants / Q000627:therapeutic use*; D001835:Body Weight; D002986:Clinical Trials as Topic; D003258:Consumer Behavior; D003913:Dextroamphetamine / Q000627:therapeutic use*; D004038:Diet, Reducing; D005069:Evaluation Studies as Topic; D001068:Feeding and Eating Disorders / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000628:therapy*; D010919:Placebos
D001067:Appetite Depressants; D007093:Imidazoles; D007211:Indoles; D010919:Placebos; D003913:Dextroamphetamine